§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇨🇳China Fees verified 12 September 2026	🇺🇸United States Fees verified 12 September 2026
Authority & dossier
Fee confirmation	Fees verified 12 September 2026	Fees verified 12 September 2026
Regulatory authority	NMPA	FDA
English submissions	No	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	None	None
Reference agencies	FDA, EMA, MHRA, PMDA +2	Not stated
Lead pathway (timeline & fees), New Drug Application (Class 1), Innovative Drug · New Drug Application, 505(b)(1)
Pathway name	New Drug Application (Class 1), Innovative Drug	New Drug Application, 505(b)(1)
Approval timeline	200-365 days	304-365 days
Headline fee and pathway	CNY 432,000, New Drug Application (Class 1), Innovative Drugconditional on other, place of manufacture	USD 4,682,003, New Drug Application, 505(b)(1)conditional on other
Recurring charges	CNY 227,200 every 5 years, per registration, overseas produced. Provinces set the domestic rate.	USD 442,213 a year, per product
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	No	No
Local responsible person	Yes	Yes
RP role	Authorised Agent (境内代理人): Chinese-incorporated entity responsible for NMPA communications, pharmacovigilance reporting, recall coordination, and pharmacovigilance system master file maintenance. The MAH must also appoint a qualified person for pharmacovigilance and a qualified person for quality.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	5 designations	6 designations
Examples	Breakthrough Therapy Designation (突破性治疗药物), Priority Review (优先审评), Conditional Approval (附条件批准) +2	Priority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3
Post-approval lifecycle
Variations framework	Post-approval changes classified as Major (重大), Moderate (中等), and Minor (微小) variations, broadly aligned with ICH Q12 principles but with China-specific procedures published in the 2021 NMPA Guideline on Post-Approval Changes.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Marketing authorisations are valid for 5 years with mandatory renewal. Renewal application due ≥6 months before expiry; renewal review can take 90 to 180 working days.	FDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Pharmacovigilance system aligned with ICH E2D/E2E since the 2021 Good Pharmacovigilance Practice (GVP) for Drugs entered force. PSURs follow ICH E2C(R2). MAH must establish a pharmacovigilance system, appoint a qualified person for pharmacovigilance (PV-QP), and report to the National Center for ADR Monitoring.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-90 days	30-30 days
GCP standard	Chinese GCP (2020 revision, ICH E6(R2) aligned)	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	No	No
HTA required	Yes	No
HTA body	National Healthcare Security Administration (NHSA), Centre for Medical Service Information	ICER (Institute for Clinical and Economic Review), independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

ChinaFees verified 12 September 2026
United StatesFees verified 12 September 2026

Regulatory authority

ChinaNMPA
United StatesFDA

English submissions

ChinaNo
United StatesYes

CTD accepted

ChinaYes
United StatesYes

eCTD accepted

ChinaYes
United StatesYes

Reliance pathway

ChinaNone
United StatesNone

Reference agencies

ChinaFDA, EMA, MHRA, PMDA +2
United StatesNot stated

Lead pathway (timeline & fees), New Drug Application (Class 1), Innovative Drug · New Drug Application, 505(b)(1)

Pathway name

ChinaNew Drug Application (Class 1), Innovative Drug
United StatesNew Drug Application, 505(b)(1)

Approval timeline

China200-365 days
United States304-365 days

Headline fee and pathway

ChinaCNY 432,000, New Drug Application (Class 1), Innovative Drugconditional on other, place of manufacture
United StatesUSD 4,682,003, New Drug Application, 505(b)(1)conditional on other

Recurring charges

ChinaCNY 227,200 every 5 years, per registration, overseas produced. Provinces set the domestic rate.
United StatesUSD 442,213 a year, per product

Local representative

ChinaRequired
United StatesNot required

Local manufacturing

ChinaNot required
United StatesNot required

GMP inspection

ChinaRequired
United StatesRequired

MAH & local presence

Local entity required

ChinaNo
United StatesNo

Local responsible person

ChinaYes
United StatesYes

RP role

ChinaAuthorised Agent (境内代理人): Chinese-incorporated entity responsible for NMPA communications, pharmacovigilance reporting, recall coordination, and pharmacovigilance system master file maintenance. The MAH must also appoint a qualified person for pharmacovigilance and a qualified person for quality.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

China5 designations
United States6 designations

Examples

ChinaBreakthrough Therapy Designation (突破性治疗药物), Priority Review (优先审评), Conditional Approval (附条件批准) +2
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3

Post-approval lifecycle

Variations framework

ChinaPost-approval changes classified as Major (重大), Moderate (中等), and Minor (微小) variations, broadly aligned with ICH Q12 principles but with China-specific procedures published in the 2021 NMPA Guideline on Post-Approval Changes.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

ChinaMarketing authorisations are valid for 5 years with mandatory renewal. Renewal application due ≥6 months before expiry; renewal review can take 90 to 180 working days.
United StatesFDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

ChinaPharmacovigilance system aligned with ICH E2D/E2E since the 2021 Good Pharmacovigilance Practice (GVP) for Drugs entered force. PSURs follow ICH E2C(R2). MAH must establish a pharmacovigilance system, appoint a qualified person for pharmacovigilance (PV-QP), and report to the National Center for ADR Monitoring.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

ChinaAvailable
United StatesAvailable

Compassionate Use

ChinaAvailable
United StatesAvailable

Emergency Import

ChinaAvailable
United StatesAvailable

Parallel Import

ChinaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

ChinaRequired
United StatesRequired

Ethics approval

ChinaYes
United StatesYes

CTA timeline

China60-90 days
United States30-30 days

GCP standard

ChinaChinese GCP (2020 revision, ICH E6(R2) aligned)
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

ChinaRegulated
United StatesFree pricing

Reference pricing

ChinaNo
United StatesNo

HTA required

ChinaYes
United StatesNo

HTA body

ChinaNational Healthcare Security Administration (NHSA), Centre for Medical Service Information
United StatesICER (Institute for Clinical and Economic Review), independent, non-binding